ArticleDiabetes2025
Regulation of Type 1 Diabetes via Brown Adipocyte-Secreted Proteins and the Novel Glucagon Regulator Nidogen-2.
Article in Diabetes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Primary cilia regulate GLP-1 signaling in pancreatic β cells.Molecular metabolism · 2026Article
- Cold Exposure Induces Swine Brown Adipocytes to Display an Island-like Distribution with Atypical Characteristics.International journal of molecular sciences · 2025Article
- Automated Supraclavicular Brown Adipose Tissue Segmentation in Computed Tomography Using nnU-Net: Integration with TotalSegmentator.Diagnostics (Basel, Switzerland) · 2024Article
Corrections and comments
- Update of
Authors and funding
7 authors.
Funding
Abstract
Current treatments for type 1 diabetes (T1D) focus on insulin replacement. We demonstrated the therapeutic potential of a secreted protein fraction from embryonic brown adipose tissue (BAT) that mediates insulin receptor-dependent recovery of euglycemia in a T1D, nonobese diabetic (NOD) mouse model, by suppressing glucagon secretion. This fraction promoted white adipocyte differentiation and browning, maintained healthy BAT, and enhanced glucose uptake in adipose tissue, skeletal muscle, and liver. We identified nidogen-2 as a critical BAT-secreted protein that reverses hyperglycemia in NOD mice, inhibits glucagon secretion from pancreatic α-cells, and mimics other actions of the entire secreted fraction. Secretions from a BAT cell line with siRNA knockdown of nidogen-2 failed to inhibit glucagon secretion and restore euglycemia. These findings demonstrate that BAT-secreted peptides represent a novel therapeutic approach to diabetes management. Furthermore, our research reveals a novel signaling role for nidogen-2 beyond its traditional classification as an extracellular matrix protein. ARTICLE HIGHLIGHTS: Large embryonic brown adipose tissue-secreted proteins (CB-100) suppress glucagon and normalize glycemia in mice with type 1 diabetes (T1D) without changing insulin. CB-100 prevented T1D-induced whitening, promoted browning of adipose tissue, and enhanced glucose uptake via an insulin receptor-dependent pathway. Within CB-100, nidogen-2 regulated glucagon secretion and restored euglycemia in T1D. Nidogen-2 and CB-100 unveil a therapeutic strategy for diabetes management beyond insulin-centric paradigms by modulating glucagon secretion and enhancing glucose metabolism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.